Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 129-135 , February 2009

Development of [90Y]DOTA-conjugated bisphosphonate for treatment of painful bone metastases

  • Kazuma Ogawa

      Affiliations

    • Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 76 265 2476; fax: +81 76 234 4245.
    • ,
  • Hidekazu Kawashima

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
    • Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan
    • ,
  • Kazuhiro Shiba

      Affiliations

    • Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
    • ,
  • Kohshin Washiyama

      Affiliations

    • Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0942, Japan
    • ,
  • Mitsuyoshi Yoshimoto

      Affiliations

    • Division of Health Sciences, Graduate School of Medical Science, Kanazawa University, Kanazawa 920-0942, Japan
    • ,
  • Yasushi Kiyono

      Affiliations

    • Biomedical Imaging Research Center, University of Fukui, Yoshida-gun 910-1193, Japan
    • Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan
    • ,
  • Masashi Ueda

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan
    • Radioisotopes Research Laboratory, Kyoto University Hospital, Faculty of Medicine, Kyoto University, Kyoto 606-8507, Japan
    • ,
  • Hirofumi Mori

      Affiliations

    • Advanced Science Research Center, Kanazawa University, Kanazawa 920-8640, Japan
    • ,
  • Hideo Saji

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Kyoto University, Kyoto 606-8501, Japan

Received 19 December 2007 ,Revised 23 September 2008 ,Accepted 19 November 2008.

References 

  1. Portenoy RK, Payne D, Jacobsen P. Breakthrough pain: characteristics and impact in patients with cancer pain. Pain. 1999;81:129–134
  2. Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999;353:1695–1700
  3. Mercadante S. Malignant bone pain: pathophysiology and treatment. Pain. 1997;69:1–18
  4. Arcangeli G, Giovinazzo G, Saracino B, D'Angelo L, Giannarelli D, Micheli A. Radiation therapy in the management of symptomatic bone metastases: the effect of total dose and histology on pain relief and response duration. Int J Radiat Oncol Biol Phys. 1998;42:1119–1126
  5. Lewington VJ. Bone-seeking radionuclides for therapy. J Nucl Med. 2005;46(Suppl 1):38S–47S
  6. Kutzner J, Hahn K, Grimm W, Rosler HP, Eckmann A, Bender S. Yttrium-90–citrat zur schmerztherapie bei knochenmetastasen ([Yttrium–citrate for pain-therapy by bone metastases]), NUC Compact. 1990;21:128–132
  7. Rosch F, Herzog H, Plag C, Neumaier B, Braun U, Muller-Gartner HW, et al. Radiation doses of yttrium-90 citrate and yttrium-90 EDTMP as determined via analogous yttrium-86 complexes and positron emission tomography. Eur J Nucl Med. 1996;23:958–966
  8. Ogawa K, Mukai T, Arano Y, Hanaoka H, Hashimoto K, Nishimura H, et al. Design of a radiopharmaceutical for the palliation of painful bone metastases: rhenium-186-labeled bisphosphonate derivative. J Labelled Comp Radiopharm. 2004;47:753–761
  9. Ogawa K, Mukai T, Arano Y, Ono M, Hanaoka H, Ishino S, et al. Development of a rhenium-186-labeled MAG3-conjugated bisphosphonate for the palliation of metastatic bone pain based on the concept of bifunctional radiopharmaceuticals. Bioconjug Chem. 2005;16:751–757
  10. Ogawa K, Mukai T, Arano Y, Otaka A, Ueda M, Uehara T, et al. Rhemium-186-monoaminemonoamidedithiol-conjugated bisphosphonate derivatives for bone pain palliation. Nucl Med Biol. 2006;33:513–520
  11. Ogawa K, Mukai T, Asano D, Kawashima H, Kinuya S, Shiba K, et al. Therapeutic effects of a 186Re-complex-conjugated bisphosphonate for the palliation of metastatic bone pain in an animal model. J Nucl Med. 2007;48:122–127
  12. Uehara T, Jin ZL, Ogawa K, Akizawa H, Hashimoto K, Nakayama M, et al. Assessment of 186Re chelate-conjugated bisphosphonate for the development of new radiopharmaceuticals for bones. Nucl Med Biol. 2007;34:79–87
  13. Ogawa K, Mukai T, Kawai K, Takamura N, Hanaoka H, Hashimoto K, et al. Usefulness of competitive inhibitors of protein binding for improving the pharmacokinetics of 186Re-MAG3-conjugated bisphosphonate (186Re-MAG3-HBP), an agent for treatment of painful bone metastases. Eur J Nucl Med Mol Imaging. 2009;36:115–121
  14. de Klerk JM, van Dieren EB, van het Schip AD, Hoekstra A, Zonnenberg BA, van Dijk A, et al. Bone marrow absorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med. 1996;37:38–41
  15. Liepe K, Hliscs R, Kropp J, Runge R, Knapp FF, Franke WG. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases. J Nucl Med. 2003;44:953–960
  16. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46:1023–1027
  17. de Jong M, Bakker WH, Krenning EP, Breeman WA, van der Pluijm ME, Bernard BF, et al. Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy. Eur J Nucl Med. 1997;24:368–371
  18. Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with 90Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med. 2001;28:426–434
  19. Goeckeler WF, Edwards B, Volkert WA, Holmes RA, Simon J, Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med. 1987;28:495–504
  20. Zhang S, Gangal G, Uludag H. ‘Magic bullets’ for bone diseases: progress in rational design of bone-seeking medicinal agents. Chem Soc Rev. 2007;36:507–531
  21. Subramanian G, McAfee JG, Blair RJ, Mehter A, Connor T. Tc-EHDP: a potential radiopharmaceutical for skeletal imaging. J Nucl Med. 1972;13:947–950
  22. Libson K, Deutsch E, Barnett BL. Structural characterization of a technetium-99-diphosphonate complex. Implications for the chemistry of technetium-99m skeletal imaging agents. J Am Chem Soc. 1980;102:2476–2478
  23. Wilson GM, Pinkerton TC. Determination of charge and size of technetium diphosphonate complexes by anion-exchange liquid chromatography. Anal Chem. 1985;57:246–253
  24. Deutsch E, Libson K, Vanderheyden JL, Ketring AR, Maxon HR. The chemistry of rhenium and technetium as related to the use of isotopes of these elements in therapeutic and diagnostic nuclear medicine. Nucl Med Biol. 1986;13:465–477
  25. de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646–651
  26. Ogawa K, Mukai T, Inoue Y, Ono M, Saji H. Development of a novel 99mTc-chelate-conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J Nucl Med. 2006;47:2042–2047
  27. Palma E, Oliveira BL, Correia JD, Gano L, Maria L, Santos IC, et al. A new bisphosphonate-containing 99mTc(I) tricarbonyl complex potentially useful as bone-seeking agent: synthesis and biological evaluation. J Biol Inorg Chem. 2007;12:667–679
  28. Verbeke K, Rozenski J, Cleynhens B, Vanbilloen H, de Groot T, Weyns N, et al. Development of a conjugate of 99mTc-EC with aminomethylenediphosphonate in the search for a bone tracer with fast clearance from soft tissue. Bioconjug Chem. 2002;13:16–22
  29. Kubicek V, Rudovsky J, Kotek J, Hermann P, Vander Elst L, Muller RN, et al. A bisphosphonate monoamide analogue of DOTA: a potential agent for bone targeting. J Am Chem Soc. 2005;127:16477–16485
  30. Meyer JL, Nancollas GH. The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite. Calcif Tissue Res. 1973;13:295–303
  31. van Beek E, Hoekstra M, van de Ruit M, Lowik C, Papapoulos S. Structural requirements for bisphosphonate actions in vitro. J Bone Miner Res. 1994;9:1875–1882
  32. Larsen RH, Murud KM, Akabani G, Hoff P, Bruland OS, Zalutsky MR. At- and 131I-labeled bisphosphonates with high in vivo stability and bone accumulation. J Nucl Med. 1999;40:1197–1203
  33. Laznicek M, Laznickova A, Budsky F, Prokop J, Kopicka K. Comparison of biological characteristics of EDTMP complexes with 99mTc, 111In and 153Sm in rats. Appl Radiat Isot. 1994;45:949–953
  34. Ketring AR. Sm-EDTMP and 186Re-HEDP as bone therapeutic radiopharmaceuticals. Int J Rad Appl Instrum B. 1987;14:223–232
  35. Das T, Chakraborty S, Unni PR, Banerjee S, Samuel G, Sarma HD, et al. Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation. Appl Radiat Isot. 2002;57:177–184

PII: S0969-8051(08)00246-1

doi: 10.1016/j.nucmedbio.2008.11.007

Nuclear Medicine and Biology
Volume 36, Issue 2 , Pages 129-135 , February 2009

Article Tools

* Image Usage & Resolution